3
|
Kawarai Y, Orita S, Nakamura J, Miyamoto S, Suzuki M, Inage K, Hagiwara S, Suzuki T, Nakajima T, Akazawa T, Ohtori S. Analgesic Effect of Duloxetine on an Animal Model of Monosodium Iodoacetate-Induced Hip Osteoarthritis. J Orthop Res 2020; 38:422-430. [PMID: 31538672 DOI: 10.1002/jor.24480] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Accepted: 09/13/2019] [Indexed: 02/04/2023]
Abstract
We investigated the efficacy of duloxetine on hyperalgesia, histopathological and radiographic findings, pain-related sensory innervation of dorsal-root ganglia (DRG), and spinal changes in a rat model of induced hip osteoarthritis (OA). The right hip joints of male Sprague-Dawley rats (n = 6 rats/group) in the Sham group were injected with 25 μl of sterile saline and 25 μl of sterile saline with 2 mg of monosodium iodoacetate (MIA) were injected to the MIA + Vehicle and MIA + Duloxetine groups. We injected duloxetine 20 mg/kg intraperitoneally in the MIA + Duloxetine group 28 days after injection, whereas rats in the MIA + Vehicle group were injected with 0.5 ml of 20% dimethyl sulfoxide. We assessed hyperalgesia, histopathological changes, immunoreactive (-ir) neurons for calcitonin gene-related peptide and activating transcription factor 3 in DRG, and immunoreactive neurons for ionized-calcium-binding adaptor molecule 1 (Iba1) in the dorsal horn of the spinal cord. MIA administration into the hip joint let to mechanical hyperalgesia of the ipsilateral hind paw (p < 0.05). A single injection of duloxetine significantly attenuated it in induced hip OA (p < 0.05) and suppressed the number of Iba1-ir microglia of the ipsilateral dorsal horn (p < 0.05). These results suggest that a single injection of duloxetine suppressed mechanical hyperalgesia and may influence the expression of Iba1 in the microglia of the ipsilateral dorsal horn in the MIA-induced hip OA. This finding implies the inhibitory effects of duloxetine against neuropathic pain, which may lead to a change of microglial activities. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:422-430, 2020.
Collapse
Affiliation(s)
- Yuya Kawarai
- Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan
| | - Sumihisa Orita
- Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan
| | - Junichi Nakamura
- Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan
| | - Shuichi Miyamoto
- Department of Orthopaedic Surgery, Matsudo City General Hospital, 993-1 Sendabori, Matsudo, Chiba, 270-2296, Japan
| | - Miyako Suzuki
- Department of Bioenvironmental Medicine, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8677, Japan
| | - Kazuhide Inage
- Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan
| | - Shigeo Hagiwara
- Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan
| | - Takane Suzuki
- Department of Bioenvironmental Medicine, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8677, Japan
| | - Takayuki Nakajima
- Department of Orthopaedic Surgery, Eastern Chiba Medical Center, 3-6-2 Okayamadai, Togane, Chiba, 283-8686, Japan
| | - Tsutomu Akazawa
- Department of Orthopaedic Surgery, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan
| | - Seiji Ohtori
- Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan
| |
Collapse
|
4
|
Moriguchi S, Takano H, Kimura Y, Nagashima T, Takahata K, Kubota M, Kitamura S, Ishii T, Ichise M, Zhang MR, Shimada H, Mimura M, Meyer JH, Higuchi M, Suhara T. Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2. Int J Neuropsychopharmacol 2017; 20:957-962. [PMID: 29016875 PMCID: PMC5716070 DOI: 10.1093/ijnp/pyx069] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/25/2017] [Accepted: 07/28/2017] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND The norepinephrine transporter in the brain has been targeted in the treatment of psychiatric disorders. Duloxetine is a serotonin and norepinephrine reuptake inhibitor that has been widely used for the treatment of depression. However, the relationship between dose and plasma concentration of duloxetine and norepinephrine transporter occupancy in the human brain has not been determined. In this study, we examined norepinephrine transporter occupancy by different doses of duloxetine. METHODS We calculated norepinephrine transporter occupancies from 2 positron emission tomography scans using (S,S)-[18F]FMeNER-D2 before and after a single oral dose of duloxetine (20 mg, n = 3; 40 mg, n = 3; 60 mg, n =2). Positron emission tomography scans were performed from 120 to 180 minutes after an i.v. bolus injection of (S,S)-[18F]FMeNER-D2. Venous blood samples were taken to measure the plasma concentration of duloxetine just before and after the second positron emission tomography scan. RESULTS Norepinephrine transporter occupancy by duloxetine was 29.7% at 20 mg, 30.5% at 40 mg, and 40.0% at 60 mg. The estimated dose of duloxetine inducing 50% norepinephrine transporter occupancy was 76.8 mg, and the estimated plasma drug concentration inducing 50% norepinephrine transporter occupancy was 58.0 ng/mL. CONCLUSIONS Norepinephrine transporter occupancy by clinical doses of duloxetine was approximately 30% to 40% in human brain as estimated using positron emission tomography with (S,S)-[18F]FMeNER-D2.
Collapse
Affiliation(s)
- Sho Moriguchi
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Moriguchi, Takano, Kimura, Nagashima, Takahata, Kubota, Kitamura, Ishii, Ichise, Zhang, Shimada, Higuchi, and Suhara); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Drs Moriguchi, Takahata, and Mimura); Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada (Drs Moriguchi and Meyer); Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura),Correspondence: Sho Moriguchi, MD, PhD, Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, Chiba 263-8555, Japan ()
| | - Harumasa Takano
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Moriguchi, Takano, Kimura, Nagashima, Takahata, Kubota, Kitamura, Ishii, Ichise, Zhang, Shimada, Higuchi, and Suhara); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Drs Moriguchi, Takahata, and Mimura); Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada (Drs Moriguchi and Meyer); Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura)
| | - Yasuyuki Kimura
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Moriguchi, Takano, Kimura, Nagashima, Takahata, Kubota, Kitamura, Ishii, Ichise, Zhang, Shimada, Higuchi, and Suhara); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Drs Moriguchi, Takahata, and Mimura); Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada (Drs Moriguchi and Meyer); Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura)
| | - Tomohisa Nagashima
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Moriguchi, Takano, Kimura, Nagashima, Takahata, Kubota, Kitamura, Ishii, Ichise, Zhang, Shimada, Higuchi, and Suhara); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Drs Moriguchi, Takahata, and Mimura); Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada (Drs Moriguchi and Meyer); Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura)
| | - Keisuke Takahata
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Moriguchi, Takano, Kimura, Nagashima, Takahata, Kubota, Kitamura, Ishii, Ichise, Zhang, Shimada, Higuchi, and Suhara); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Drs Moriguchi, Takahata, and Mimura); Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada (Drs Moriguchi and Meyer); Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura)
| | - Manabu Kubota
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Moriguchi, Takano, Kimura, Nagashima, Takahata, Kubota, Kitamura, Ishii, Ichise, Zhang, Shimada, Higuchi, and Suhara); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Drs Moriguchi, Takahata, and Mimura); Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada (Drs Moriguchi and Meyer); Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura)
| | - Soichiro Kitamura
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Moriguchi, Takano, Kimura, Nagashima, Takahata, Kubota, Kitamura, Ishii, Ichise, Zhang, Shimada, Higuchi, and Suhara); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Drs Moriguchi, Takahata, and Mimura); Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada (Drs Moriguchi and Meyer); Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura)
| | - Tatsuya Ishii
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Moriguchi, Takano, Kimura, Nagashima, Takahata, Kubota, Kitamura, Ishii, Ichise, Zhang, Shimada, Higuchi, and Suhara); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Drs Moriguchi, Takahata, and Mimura); Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada (Drs Moriguchi and Meyer); Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura)
| | - Masanori Ichise
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Moriguchi, Takano, Kimura, Nagashima, Takahata, Kubota, Kitamura, Ishii, Ichise, Zhang, Shimada, Higuchi, and Suhara); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Drs Moriguchi, Takahata, and Mimura); Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada (Drs Moriguchi and Meyer); Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura)
| | - Ming-Rong Zhang
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Moriguchi, Takano, Kimura, Nagashima, Takahata, Kubota, Kitamura, Ishii, Ichise, Zhang, Shimada, Higuchi, and Suhara); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Drs Moriguchi, Takahata, and Mimura); Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada (Drs Moriguchi and Meyer); Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura)
| | - Hitoshi Shimada
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Moriguchi, Takano, Kimura, Nagashima, Takahata, Kubota, Kitamura, Ishii, Ichise, Zhang, Shimada, Higuchi, and Suhara); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Drs Moriguchi, Takahata, and Mimura); Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada (Drs Moriguchi and Meyer); Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura)
| | - Masaru Mimura
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Moriguchi, Takano, Kimura, Nagashima, Takahata, Kubota, Kitamura, Ishii, Ichise, Zhang, Shimada, Higuchi, and Suhara); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Drs Moriguchi, Takahata, and Mimura); Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada (Drs Moriguchi and Meyer); Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura)
| | - Jeffrey H Meyer
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Moriguchi, Takano, Kimura, Nagashima, Takahata, Kubota, Kitamura, Ishii, Ichise, Zhang, Shimada, Higuchi, and Suhara); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Drs Moriguchi, Takahata, and Mimura); Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada (Drs Moriguchi and Meyer); Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura)
| | - Makoto Higuchi
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Moriguchi, Takano, Kimura, Nagashima, Takahata, Kubota, Kitamura, Ishii, Ichise, Zhang, Shimada, Higuchi, and Suhara); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Drs Moriguchi, Takahata, and Mimura); Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada (Drs Moriguchi and Meyer); Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura)
| | - Tetsuya Suhara
- Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Moriguchi, Takano, Kimura, Nagashima, Takahata, Kubota, Kitamura, Ishii, Ichise, Zhang, Shimada, Higuchi, and Suhara); Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan (Drs Moriguchi, Takahata, and Mimura); Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada (Drs Moriguchi and Meyer); Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan (Dr Takano); Department of Clinical and Experimental Neuroimaging, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan (Dr Kimura)
| |
Collapse
|